EUVIMEDEUVIMED entdecken
Crossref

Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation—A study from the neuro-urology committee of the French Association of Urology

Stéphanie Delaval, Pierre-Luc Dequirez iD, Claire Hentzen, Maximilien Baron, Eva Mille, François Tariel, Benoit Peyronnet, Marie-Aimée Perrouin-Verbe, Adeline Pierache iD, Emmanuel Chartier-Kastler, Grégoire Capon, Jean-Nicolas Cornu und 10 weitere

Multiple Sclerosis Journal · 2023

DOI: 10.1177/13524585231174580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal, 2023. Verfasst von Stéphanie Delaval und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Lille, Claude Huriez Hospital, Lille University Hospital, Lille, France. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urinary Bladder, Overactive, Neuromuscular Agents, Multiple Sclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While intravesical injections of botulinum neurotoxin A (BoNT-A) are currently recommended for patients experiencing refractory neurogenic overactive bladder and/or detrusor overactivity (OAB/DO), it is unclear how much this therapy is effective and sustainable in the long-term in patients with multiple sclerosis (MS).

Objectives

To assess the mid-term continuation rate of BoNT-A injections to treat neurogenic OAB/DO in MS patients and to investigate MS-specific risk factors for discontinuation.

Methods

This retrospective study involved 11 French university hospital centers. All MS patients who received BoNT-A to treat neurogenic OAB/DO between 2008 and 2013 and were subsequently followed up for at least 5 years were eligible.

Results

Of the 196 MS patients included, 159 (81.1%) were still under BoNT-A 5 years after the first injection. The combination of the Expanded Disability Status Scale (EDSS < 6 or ⩾ 6) and of the MS type (relapsing–remitting vs progressive) predicted the risk of discontinuation. This risk was 5.5% for patients with no risk factor, whereas patients presenting with one or two risk factors were 3.3 and 5.7 times more likely to discontinue, respectively.

Conclusion

BoNT-A is a satisfying mid-term neurogenic OAB/DO therapy for most MS patients. Combining EDSS and MS type could help predict BoNT-A discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AUrinary Bladder, OveractiveNeuromuscular AgentsMultiple SclerosisUrologyUrinary Bladder, NeurogenicHumansAdministration, IntravesicalRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Symptomatic treatmentdetrusor overactivityneurogenic bladderself-catheterizationurology

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Urology, University of Lille, Claude Huriez Hospital, Lille University Hospital, Lille, France.
  • GRC 001, GREEN Groupe de Recherche Clinique en Neuro-Urologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Tenon Academic Hospital, Paris, France.
  • Department of Urology, Hotel Dieu Hospital, University of Nantes, Nantes, France.
  • Department of Urology, Assistance-Publique-Hôpitaux de Marseille (AP-HM), La Conception Academic Hospital, Marseille, France.
  • Department of Urology, University of Rennes, Rennes Academic Hospital, Rennes, France.
  • Department of Biostatistics, CHU Lille, Lille, France.

ORCID-Profile: Pierre-Luc Dequirez, Adeline Pierache

Zitieren

APA

Delaval, S., Dequirez, P. L., Hentzen, C., Baron, M., Mille, E., Tariel, F., Peyronnet, B., Perrouin-Verbe, M. A., Pierache, A., Chartier-Kastler, E., Capon, G., Cornu, J. N., Castel-Lacanal, E., Gamé, X., Karsenty, G., Ruffion, A., Denys, P., Even, A., Joussain, C., …, & Biardeau, X. (2023). Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation—A study from the neuro-urology committee of the French Association of Urology. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585231174580

Vancouver

Delaval S, Dequirez PL, Hentzen C, Baron M, Mille E, Tariel F, et al. Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation—A study from the neuro-urology committee of the French Association of Urology. Multiple Sclerosis Journal. 2023. doi:10.1177/13524585231174580

BibTeX
@article{Delaval2023,
  author = {Delaval, Stéphanie and Dequirez, Pierre-Luc and Hentzen, Claire and Baron, Maximilien and Mille, Eva and Tariel, François and Peyronnet, Benoit and Perrouin-Verbe, Marie-Aimée and Pierache, Adeline and Chartier-Kastler, Emmanuel and Capon, Grégoire and Cornu, Jean-Nicolas and Castel-Lacanal, Evelyne and Gamé, Xavier and Karsenty, Gilles and Ruffion, Alain and Denys, Pierre and Even, Alexia and Joussain, Charles and Amarenco, Gérard and Phé, Véronique and Biardeau, Xavier},
  title = {Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation—A study from the neuro-urology committee of the French Association of Urology},
  journal = {Multiple Sclerosis Journal},
  year = {2023},
  doi = {10.1177/13524585231174580}
}
Kostenlos starten →